BCL2 and non-Hodgkin lymphoma: Only very recently, a new orally available high-affinity Bcl-2 selective BH3 mimetic, namely ABT-199, was developed and was shown to have a better toxicity profile, while being equally as effective or even slightly superior in hematological malignancies depending mainly on Bcl-2 (such as CLL and non-Hodgkin lymphoma) [8, 9].